| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Acute-On-Chronic Liver Failure | 15 | 2020 | 237 | 6.84 | Why? |
| Liver Cirrhosis | 25 | 2020 | 1810 | 4.77 | Why? |
| Hepatitis, Alcoholic | 8 | 2019 | 61 | 4.24 | Why? |
| Hypertension, Portal | 7 | 2018 | 73 | 3.24 | Why? |
| Budd-Chiari Syndrome | 3 | 2018 | 31 | 2.11 | Why? |
| Liver | 16 | 2019 | 4007 | 2.10 | Why? |
| Portal Vein | 4 | 2018 | 193 | 1.69 | Why? |
| Hepatitis B, Chronic | 8 | 2019 | 616 | 1.68 | Why? |
| End Stage Liver Disease | 4 | 2020 | 418 | 1.60 | Why? |
| Esophageal and Gastric Varices | 4 | 2019 | 117 | 1.49 | Why? |
| Jugular Veins | 2 | 2018 | 52 | 1.40 | Why? |
| Hepatic Veins | 2 | 2018 | 54 | 1.39 | Why? |
| Liver Neoplasms | 9 | 2020 | 1666 | 1.34 | Why? |
| Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 198 | 1.33 | Why? |
| Carcinoma, Hepatocellular | 8 | 2020 | 1222 | 1.28 | Why? |
| Serum Albumin, Human | 2 | 2019 | 265 | 1.24 | Why? |
| Hepatic Encephalopathy | 5 | 2018 | 88 | 1.22 | Why? |
| Hepatitis, Autoimmune | 3 | 2019 | 254 | 1.20 | Why? |
| Medical History Taking | 2 | 2018 | 350 | 1.18 | Why? |
| Hepatitis B | 5 | 2019 | 888 | 1.11 | Why? |
| Receptors, Cell Surface | 2 | 2018 | 586 | 1.05 | Why? |
| Hepatitis B virus | 9 | 2019 | 882 | 1.04 | Why? |
| Elasticity Imaging Techniques | 4 | 2018 | 194 | 1.03 | Why? |
| Hepacivirus | 6 | 2019 | 1509 | 1.00 | Why? |
| Ultrasonography, Interventional | 2 | 2018 | 560 | 0.98 | Why? |
| Antigens, CD | 2 | 2018 | 984 | 0.97 | Why? |
| Hepatitis B Surface Antigens | 4 | 2019 | 305 | 0.96 | Why? |
| Hemorrhage | 3 | 2019 | 3013 | 0.89 | Why? |
| Liver Failure, Acute | 4 | 2019 | 279 | 0.88 | Why? |
| Splenomegaly | 2 | 2018 | 43 | 0.87 | Why? |
| Liver Transplantation | 7 | 2018 | 2864 | 0.82 | Why? |
| Liver Regeneration | 1 | 2019 | 38 | 0.81 | Why? |
| Sclerotherapy | 2 | 2017 | 23 | 0.80 | Why? |
| Non-alcoholic Fatty Liver Disease | 4 | 2018 | 907 | 0.79 | Why? |
| Streptococcus gallolyticus | 1 | 2018 | 7 | 0.79 | Why? |
| Hepatitis C, Chronic | 6 | 2019 | 973 | 0.78 | Why? |
| Single-Balloon Enteroscopy | 1 | 2018 | 5 | 0.78 | Why? |
| Spumavirus | 1 | 2019 | 14 | 0.78 | Why? |
| Bromocriptine | 1 | 2019 | 42 | 0.78 | Why? |
| India | 18 | 2020 | 11875 | 0.78 | Why? |
| Receptors, Interleukin | 1 | 2019 | 83 | 0.76 | Why? |
| Pancytopenia | 2 | 2018 | 113 | 0.76 | Why? |
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2018 | 16 | 0.75 | Why? |
| Nestin | 1 | 2018 | 12 | 0.74 | Why? |
| Vascular Grafting | 1 | 2018 | 23 | 0.73 | Why? |
| Drug Resistance | 2 | 2018 | 395 | 0.73 | Why? |
| Enbucrilate | 1 | 2017 | 7 | 0.73 | Why? |
| Paracentesis | 1 | 2017 | 25 | 0.72 | Why? |
| Albuminuria | 1 | 2019 | 164 | 0.72 | Why? |
| Carnitine O-Palmitoyltransferase | 1 | 2017 | 11 | 0.71 | Why? |
| Fatty Liver, Alcoholic | 1 | 2017 | 13 | 0.71 | Why? |
| Lipid Metabolism, Inborn Errors | 1 | 2017 | 9 | 0.71 | Why? |
| Fluoroscopy | 1 | 2018 | 140 | 0.70 | Why? |
| Prednisolone | 2 | 2019 | 443 | 0.70 | Why? |
| Sodium Tetradecyl Sulfate | 1 | 2017 | 1 | 0.70 | Why? |
| Ethiodized Oil | 1 | 2017 | 9 | 0.70 | Why? |
| Antiparkinson Agents | 1 | 2019 | 125 | 0.70 | Why? |
| Adrenergic beta-Antagonists | 2 | 2019 | 465 | 0.69 | Why? |
| Varicose Veins | 1 | 2017 | 30 | 0.69 | Why? |
| Carnitine | 1 | 2017 | 47 | 0.68 | Why? |
| Protein C | 1 | 2018 | 141 | 0.68 | Why? |
| Liver Cirrhosis, Alcoholic | 1 | 2017 | 32 | 0.68 | Why? |
| Hepatitis C | 3 | 2019 | 1514 | 0.68 | Why? |
| Sofosbuvir | 3 | 2019 | 518 | 0.67 | Why? |
| Cholestasis | 1 | 2018 | 114 | 0.67 | Why? |
| Vena Cava, Inferior | 1 | 2018 | 103 | 0.67 | Why? |
| Endosonography | 1 | 2018 | 150 | 0.67 | Why? |
| Balloon Occlusion | 1 | 2017 | 39 | 0.66 | Why? |
| Liver Failure | 2 | 2017 | 266 | 0.66 | Why? |
| Parkinsonian Disorders | 1 | 2019 | 118 | 0.66 | Why? |
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2018 | 237 | 0.66 | Why? |
| Endovascular Procedures | 2 | 2017 | 1302 | 0.65 | Why? |
| Gastrointestinal Hemorrhage | 3 | 2019 | 669 | 0.65 | Why? |
| Lipase | 1 | 2018 | 153 | 0.65 | Why? |
| Cell-Derived Microparticles | 1 | 2018 | 134 | 0.65 | Why? |
| Multimodal Imaging | 2 | 2018 | 534 | 0.65 | Why? |
| Cystatin C | 1 | 2017 | 125 | 0.64 | Why? |
| Metabolic Syndrome | 2 | 2017 | 810 | 0.64 | Why? |
| Blood Volume | 1 | 2017 | 90 | 0.64 | Why? |
| Iron Overload | 1 | 2018 | 113 | 0.64 | Why? |
| Image-Guided Biopsy | 1 | 2018 | 185 | 0.64 | Why? |
| ADAM17 Protein | 1 | 2018 | 221 | 0.63 | Why? |
| Bilirubin | 2 | 2017 | 503 | 0.63 | Why? |
| Tenofovir | 2 | 2019 | 449 | 0.62 | Why? |
| Cardiac Output | 1 | 2017 | 183 | 0.61 | Why? |
| JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 59 | 0.61 | Why? |
| Streptococcal Infections | 1 | 2018 | 255 | 0.58 | Why? |
| Drainage | 1 | 2018 | 414 | 0.57 | Why? |
| Promoter Regions, Genetic | 1 | 2019 | 823 | 0.57 | Why? |
| Graft Survival | 1 | 2018 | 587 | 0.56 | Why? |
| Albumins | 1 | 2017 | 324 | 0.56 | Why? |
| Adiposity | 1 | 2017 | 329 | 0.55 | Why? |
| Embolization, Therapeutic | 1 | 2017 | 269 | 0.55 | Why? |
| Creatinine | 2 | 2017 | 1443 | 0.54 | Why? |
| Fatty Liver | 3 | 2016 | 299 | 0.53 | Why? |
| Liver Diseases | 3 | 2020 | 2698 | 0.53 | Why? |
| Antigens, Differentiation | 1 | 2015 | 172 | 0.53 | Why? |
| Th17 Cells | 1 | 2019 | 657 | 0.51 | Why? |
| Amino Acids | 1 | 2017 | 552 | 0.51 | Why? |
| Candidiasis | 1 | 2017 | 334 | 0.50 | Why? |
| Drug Resistance, Microbial | 1 | 2017 | 419 | 0.50 | Why? |
| Adult | 54 | 2019 | 244371 | 0.50 | Why? |
| Male | 67 | 2020 | 367725 | 0.49 | Why? |
| MicroRNAs | 5 | 2018 | 1787 | 0.49 | Why? |
| Living Donors | 1 | 2018 | 652 | 0.48 | Why? |
| Metabolic Diseases | 1 | 2018 | 505 | 0.48 | Why? |
| Iron | 1 | 2018 | 619 | 0.48 | Why? |
| Specimen Handling | 2 | 2021 | 6190 | 0.48 | Why? |
| Hypoglycemia | 1 | 2017 | 406 | 0.47 | Why? |
| Sarcopenia | 1 | 2017 | 422 | 0.46 | Why? |
| Middle Aged | 50 | 2020 | 270681 | 0.44 | Why? |
| Hospitals, Public | 1 | 2017 | 774 | 0.44 | Why? |
| Female | 60 | 2020 | 380317 | 0.44 | Why? |
| Humans | 98 | 2021 | 930598 | 0.42 | Why? |
| Acute Kidney Injury | 4 | 2018 | 5762 | 0.42 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 451 | 0.42 | Why? |
| Muscle, Skeletal | 1 | 2017 | 915 | 0.41 | Why? |
| Soft Tissue Neoplasms | 1 | 2011 | 131 | 0.41 | Why? |
| Sustained Virologic Response | 4 | 2019 | 378 | 0.40 | Why? |
| Stents | 1 | 2017 | 916 | 0.40 | Why? |
| Evoked Potentials, Auditory | 2 | 2008 | 34 | 0.40 | Why? |
| Venous Thrombosis | 4 | 2018 | 2739 | 0.40 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 13720 | 0.40 | Why? |
| Cryogels | 3 | 2017 | 4 | 0.39 | Why? |
| Luminescent Measurements | 1 | 2015 | 924 | 0.39 | Why? |
| Hospitals, Teaching | 1 | 2017 | 1609 | 0.39 | Why? |
| Flicker Fusion | 1 | 2008 | 4 | 0.38 | Why? |
| alpha-Fetoproteins | 1 | 2009 | 72 | 0.38 | Why? |
| Asialoglycoprotein Receptor | 2 | 2018 | 3 | 0.38 | Why? |
| Prospective Studies | 17 | 2020 | 43301 | 0.38 | Why? |
| Liver Function Tests | 4 | 2020 | 1325 | 0.38 | Why? |
| Uncertainty | 1 | 2020 | 1888 | 0.38 | Why? |
| Hepatic Veno-Occlusive Disease | 1 | 2008 | 25 | 0.37 | Why? |
| Endothelial Cells | 1 | 2019 | 2048 | 0.37 | Why? |
| Bacterial Infections | 3 | 2018 | 2229 | 0.37 | Why? |
| Metformin | 1 | 2015 | 640 | 0.36 | Why? |
| Bone Neoplasms | 1 | 2011 | 287 | 0.35 | Why? |
| Tissue Donors | 1 | 2017 | 1679 | 0.35 | Why? |
| Membrane Proteins | 1 | 2018 | 1733 | 0.35 | Why? |
| Diagnostic Tests, Routine | 2 | 2020 | 2643 | 0.34 | Why? |
| Case-Control Studies | 8 | 2019 | 17671 | 0.34 | Why? |
| Rare Diseases | 1 | 2011 | 373 | 0.34 | Why? |
| Cardiomyopathies | 1 | 2017 | 997 | 0.34 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.33 | Why? |
| Portal Pressure | 2 | 2018 | 13 | 0.33 | Why? |
| Severity of Illness Index | 12 | 2020 | 48226 | 0.33 | Why? |
| Adrenal Cortex Hormones | 3 | 2019 | 6537 | 0.33 | Why? |
| Bioreactors | 2 | 2017 | 115 | 0.32 | Why? |
| Kidney Diseases | 1 | 2018 | 1434 | 0.32 | Why? |
| Insulin Resistance | 1 | 2012 | 669 | 0.31 | Why? |
| Treatment Outcome | 14 | 2019 | 51732 | 0.31 | Why? |
| Tertiary Care Centers | 3 | 2019 | 8248 | 0.31 | Why? |
| Biopsy | 4 | 2018 | 2811 | 0.31 | Why? |
| Hepatocytes | 3 | 2017 | 549 | 0.30 | Why? |
| Real-Time Polymerase Chain Reaction | 3 | 2020 | 11367 | 0.30 | Why? |
| Survival Analysis | 7 | 2019 | 7592 | 0.29 | Why? |
| Hep G2 Cells | 4 | 2019 | 391 | 0.29 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.28 | Why? |
| Ultrasonography, Doppler | 2 | 2018 | 406 | 0.28 | Why? |
| Carbamates | 2 | 2019 | 485 | 0.28 | Why? |
| Anti-Inflammatory Agents | 2 | 2018 | 6153 | 0.28 | Why? |
| Transcriptome | 2 | 2017 | 3466 | 0.28 | Why? |
| Ascites | 3 | 2019 | 65 | 0.28 | Why? |
| Asia | 4 | 2020 | 2399 | 0.28 | Why? |
| Systemic Inflammatory Response Syndrome | 4 | 2019 | 6653 | 0.28 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.27 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2019 | 2984 | 0.27 | Why? |
| Cell Proliferation | 5 | 2019 | 1973 | 0.27 | Why? |
| Renal Insufficiency, Chronic | 1 | 2018 | 2654 | 0.26 | Why? |
| Point-of-Care Testing | 1 | 2017 | 2782 | 0.26 | Why? |
| Young Adult | 15 | 2019 | 93724 | 0.26 | Why? |
| Multivariate Analysis | 4 | 2018 | 5440 | 0.26 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.26 | Why? |
| DNA, Viral | 5 | 2019 | 2521 | 0.25 | Why? |
| Viral Load | 4 | 2018 | 15850 | 0.25 | Why? |
| Postoperative Complications | 2 | 2018 | 5861 | 0.24 | Why? |
| Prognosis | 11 | 2020 | 32490 | 0.24 | Why? |
| Sepsis | 2 | 2019 | 3517 | 0.24 | Why? |
| Glucocorticoids | 4 | 2019 | 4431 | 0.24 | Why? |
| Contrast Media | 2 | 2018 | 1011 | 0.23 | Why? |
| Elasticity | 2 | 2018 | 70 | 0.23 | Why? |
| Survival Rate | 5 | 2019 | 9206 | 0.23 | Why? |
| Glomerular Filtration Rate | 2 | 2018 | 1262 | 0.23 | Why? |
| Proportional Hazards Models | 3 | 2019 | 6543 | 0.22 | Why? |
| Patient Acuity | 2 | 2020 | 1755 | 0.22 | Why? |
| Biomarkers | 8 | 2019 | 23361 | 0.22 | Why? |
| Ascitic Fluid | 2 | 2018 | 169 | 0.22 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.22 | Why? |
| RNA, Viral | 3 | 2020 | 32276 | 0.22 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.22 | Why? |
| Interferon-alpha | 2 | 2017 | 1442 | 0.22 | Why? |
| Transplant Recipients | 1 | 2017 | 4982 | 0.22 | Why? |
| Molecular Diagnostic Techniques | 1 | 2017 | 4239 | 0.21 | Why? |
| Liver, Artificial | 2 | 2017 | 48 | 0.21 | Why? |
| ROC Curve | 5 | 2018 | 6024 | 0.20 | Why? |
| Lamivudine | 1 | 2001 | 210 | 0.20 | Why? |
| Jejunostomy | 1 | 2018 | 8 | 0.19 | Why? |
| Predictive Value of Tests | 5 | 2021 | 9537 | 0.19 | Why? |
| Anastomosis, Roux-en-Y | 1 | 2018 | 24 | 0.19 | Why? |
| Adolescent | 13 | 2018 | 86841 | 0.19 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2001 | 309 | 0.19 | Why? |
| Follow-Up Studies | 4 | 2019 | 17020 | 0.19 | Why? |
| Sleep Deprivation | 1 | 2020 | 175 | 0.18 | Why? |
| gamma-Glutamyltransferase | 1 | 2018 | 101 | 0.18 | Why? |
| Urethane | 1 | 2017 | 4 | 0.18 | Why? |
| Benzimidazoles | 2 | 2018 | 275 | 0.18 | Why? |
| Gastrostomy | 1 | 2018 | 56 | 0.18 | Why? |
| Cost Savings | 1 | 2021 | 296 | 0.18 | Why? |
| Sodium Fluoride | 1 | 2017 | 16 | 0.18 | Why? |
| Aged | 17 | 2020 | 215776 | 0.18 | Why? |
| Hemostasis, Endoscopic | 1 | 2018 | 24 | 0.18 | Why? |
| Antithrombin III | 1 | 2018 | 67 | 0.18 | Why? |
| Thoracentesis | 1 | 2017 | 23 | 0.18 | Why? |
| Antiviral Agents | 7 | 2019 | 41703 | 0.18 | Why? |
| Circular Dichroism | 1 | 2017 | 154 | 0.18 | Why? |
| Retrospective Studies | 12 | 2019 | 105322 | 0.17 | Why? |
| Viscoelastic Substances | 1 | 2017 | 13 | 0.17 | Why? |
| Epithelial Cell Adhesion Molecule | 1 | 2017 | 8 | 0.17 | Why? |
| Antigens, CD34 | 1 | 2018 | 125 | 0.17 | Why? |
| Heterocyclic Compounds, 4 or More Rings | 1 | 2019 | 139 | 0.17 | Why? |
| Autocrine Communication | 1 | 2017 | 14 | 0.17 | Why? |
| Double-Blind Method | 2 | 2019 | 5988 | 0.17 | Why? |
| Protein S | 1 | 2018 | 150 | 0.17 | Why? |
| Lymphocytosis | 1 | 2018 | 122 | 0.17 | Why? |
| Fluorenes | 1 | 2018 | 101 | 0.17 | Why? |
| Pyrrolidines | 2 | 2018 | 558 | 0.17 | Why? |
| Constriction, Pathologic | 1 | 2018 | 212 | 0.17 | Why? |
| Hepatitis B e Antigens | 1 | 2017 | 99 | 0.16 | Why? |
| Genetic Markers | 1 | 2018 | 318 | 0.16 | Why? |
| Drug Therapy, Combination | 3 | 2019 | 7268 | 0.16 | Why? |
| Drugs, Generic | 1 | 2018 | 136 | 0.16 | Why? |
| RNA Interference | 2 | 2017 | 534 | 0.16 | Why? |
| Wnt Signaling Pathway | 1 | 2017 | 87 | 0.16 | Why? |
| Microarray Analysis | 1 | 2018 | 262 | 0.16 | Why? |
| Plasma | 2 | 2017 | 1809 | 0.16 | Why? |
| Receptors, Glucocorticoid | 1 | 2017 | 118 | 0.16 | Why? |
| Child | 9 | 2018 | 70012 | 0.16 | Why? |
| Hepatitis B Antibodies | 1 | 2017 | 142 | 0.16 | Why? |
| Valine | 1 | 2018 | 359 | 0.16 | Why? |
| Surgery, Computer-Assisted | 1 | 2018 | 183 | 0.15 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.15 | Why? |
| Macrophage Activation | 1 | 2018 | 315 | 0.15 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.15 | Why? |
| Neoplastic Stem Cells | 1 | 2017 | 120 | 0.15 | Why? |
| Imidazoles | 2 | 2018 | 631 | 0.15 | Why? |
| Pedigree | 1 | 2017 | 502 | 0.15 | Why? |
| Genotype | 4 | 2019 | 4697 | 0.15 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.15 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.15 | Why? |
| Nucleotides | 1 | 2017 | 212 | 0.15 | Why? |
| Sensitivity and Specificity | 5 | 2020 | 22971 | 0.15 | Why? |
| Cross-Sectional Studies | 7 | 2019 | 53120 | 0.14 | Why? |
| HeLa Cells | 1 | 2019 | 1303 | 0.14 | Why? |
| Iatrogenic Disease | 1 | 2017 | 304 | 0.14 | Why? |
| Intra-Abdominal Fat | 1 | 2017 | 227 | 0.14 | Why? |
| Diagnostic Imaging | 2 | 2018 | 1044 | 0.14 | Why? |
| Blood Pressure Determination | 1 | 2018 | 450 | 0.14 | Why? |
| Models, Animal | 1 | 2018 | 788 | 0.14 | Why? |
| Disease-Free Survival | 1 | 2019 | 1654 | 0.14 | Why? |
| Fibrosis | 1 | 2018 | 800 | 0.14 | Why? |
| PTEN Phosphohydrolase | 1 | 2014 | 70 | 0.13 | Why? |
| Genetic Therapy | 1 | 2019 | 409 | 0.13 | Why? |
| Influenza, Human | 1 | 2019 | 10779 | 0.13 | Why? |
| Tumor Necrosis Factor-alpha | 2 | 2018 | 2483 | 0.13 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.13 | Why? |
| Reproducibility of Results | 3 | 2020 | 11304 | 0.13 | Why? |
| Blood Coagulation Tests | 1 | 2019 | 855 | 0.13 | Why? |
| Hematologic Tests | 1 | 2018 | 521 | 0.13 | Why? |
| Psychiatric Status Rating Scales | 1 | 2020 | 1340 | 0.13 | Why? |
| Meta-Analysis as Topic | 2 | 2017 | 1289 | 0.13 | Why? |
| Tomography, X-Ray Computed | 5 | 2019 | 25144 | 0.13 | Why? |
| Time Factors | 5 | 2019 | 31397 | 0.12 | Why? |
| Immune Tolerance | 1 | 2018 | 608 | 0.12 | Why? |
| Apoptosis Regulatory Proteins | 1 | 2014 | 202 | 0.12 | Why? |
| Disease Progression | 3 | 2020 | 13580 | 0.12 | Why? |
| Trans-Activators | 1 | 2014 | 170 | 0.12 | Why? |
| Drug Administration Schedule | 1 | 2019 | 2324 | 0.12 | Why? |
| Drug Monitoring | 2 | 2019 | 1408 | 0.12 | Why? |
| Risk Factors | 9 | 2020 | 71621 | 0.12 | Why? |
| Administration, Oral | 1 | 2019 | 2340 | 0.12 | Why? |
| Magnetic Resonance Imaging | 2 | 2019 | 6551 | 0.11 | Why? |
| Platelet Count | 1 | 2018 | 1381 | 0.11 | Why? |
| Genetic Vectors | 1 | 2019 | 1600 | 0.11 | Why? |
| Waist Circumference | 1 | 2012 | 199 | 0.11 | Why? |
| Radiography, Abdominal | 1 | 2011 | 88 | 0.11 | Why? |
| Obesity | 1 | 2012 | 7388 | 0.11 | Why? |
| Cricetinae | 1 | 2019 | 3344 | 0.11 | Why? |
| Ribavirin | 1 | 2018 | 1182 | 0.11 | Why? |
| Organ Dysfunction Scores | 1 | 2017 | 1475 | 0.11 | Why? |
| Phenylurea Compounds | 1 | 2011 | 101 | 0.11 | Why? |
| Organophosphonates | 1 | 2011 | 85 | 0.11 | Why? |
| Recurrence | 2 | 2019 | 3675 | 0.10 | Why? |
| Carrier State | 1 | 2002 | 2100 | 0.10 | Why? |
| Child, Preschool | 4 | 2017 | 36283 | 0.10 | Why? |
| Niacinamide | 1 | 2011 | 135 | 0.10 | Why? |
| Waiting Lists | 1 | 2018 | 1388 | 0.10 | Why? |
| Dose-Response Relationship, Drug | 1 | 2019 | 3776 | 0.10 | Why? |
| Decision Support Techniques | 1 | 2017 | 903 | 0.10 | Why? |
| Antibodies, Monoclonal | 1 | 2008 | 8041 | 0.10 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.09 | Why? |
| Event-Related Potentials, P300 | 1 | 2008 | 11 | 0.09 | Why? |
| Gastroenterology | 1 | 2020 | 1352 | 0.09 | Why? |
| Pilot Projects | 1 | 2021 | 5182 | 0.09 | Why? |
| Small Molecule Libraries | 1 | 2017 | 1060 | 0.09 | Why? |
| Monocytes | 1 | 2021 | 2978 | 0.09 | Why? |
| Molecular Targeted Therapy | 1 | 2018 | 1579 | 0.09 | Why? |
| Adenine | 1 | 2011 | 463 | 0.09 | Why? |
| High-Throughput Screening Assays | 1 | 2017 | 1783 | 0.09 | Why? |
| Viral Envelope Proteins | 1 | 2020 | 3539 | 0.09 | Why? |
| Animals | 7 | 2019 | 78931 | 0.09 | Why? |
| Placenta | 1 | 2018 | 1531 | 0.08 | Why? |
| Body Mass Index | 2 | 2017 | 4306 | 0.08 | Why? |
| Oxidative Stress | 1 | 2018 | 2050 | 0.08 | Why? |
| Seroconversion | 1 | 2017 | 2515 | 0.08 | Why? |
| International Normalized Ratio | 1 | 2008 | 300 | 0.08 | Why? |
| Protein Conformation | 1 | 2017 | 4386 | 0.08 | Why? |
| Blood Platelets | 1 | 2018 | 1704 | 0.08 | Why? |
| Age Factors | 2 | 2018 | 21039 | 0.08 | Why? |
| Incidence | 2 | 2019 | 25622 | 0.08 | Why? |
| Contraindications | 1 | 2006 | 96 | 0.08 | Why? |
| Gene Expression Profiling | 1 | 2018 | 3788 | 0.08 | Why? |
| RNA-Binding Proteins | 1 | 2014 | 1022 | 0.08 | Why? |
| Graft Rejection | 1 | 2017 | 1766 | 0.08 | Why? |
| Virus Replication | 2 | 2018 | 14331 | 0.08 | Why? |
| Gene Expression Regulation | 1 | 2019 | 4020 | 0.08 | Why? |
| Patient Care Team | 1 | 2020 | 3556 | 0.08 | Why? |
| Hemodynamics | 1 | 2014 | 1562 | 0.07 | Why? |
| Blood Coagulation | 1 | 2019 | 2768 | 0.07 | Why? |
| Aged, 80 and over | 5 | 2020 | 88759 | 0.07 | Why? |
| Hospital Mortality | 3 | 2018 | 22087 | 0.07 | Why? |
| Logistic Models | 2 | 2017 | 9089 | 0.07 | Why? |
| Resilience, Psychological | 1 | 2020 | 2329 | 0.07 | Why? |
| HEK293 Cells | 1 | 2019 | 8394 | 0.07 | Why? |
| Blood Proteins | 1 | 2008 | 551 | 0.07 | Why? |
| Rats, Wistar | 2 | 2017 | 621 | 0.07 | Why? |
| Serum Albumin | 1 | 2008 | 571 | 0.07 | Why? |
| Fear | 1 | 2020 | 3607 | 0.07 | Why? |
| Disease Management | 2 | 2017 | 6841 | 0.07 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.07 | Why? |
| Infant | 2 | 2017 | 30274 | 0.07 | Why? |
| Parents | 1 | 2018 | 2758 | 0.07 | Why? |
| Infliximab | 1 | 2008 | 502 | 0.07 | Why? |
| Clinical Enzyme Tests | 1 | 2003 | 27 | 0.07 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.07 | Why? |
| Prevalence | 3 | 2018 | 25773 | 0.07 | Why? |
| Cell Line | 1 | 2019 | 12040 | 0.06 | Why? |
| Echocardiography | 1 | 2017 | 3661 | 0.06 | Why? |
| Kidney Failure, Chronic | 1 | 2018 | 3222 | 0.06 | Why? |
| Time-to-Treatment | 1 | 2018 | 5883 | 0.06 | Why? |
| Risk Assessment | 3 | 2020 | 25439 | 0.05 | Why? |
| Renal Dialysis | 1 | 2018 | 4358 | 0.05 | Why? |
| Coinfection | 2 | 2019 | 6820 | 0.05 | Why? |
| Psychometrics | 1 | 2008 | 1269 | 0.05 | Why? |
| Ultrasonography | 1 | 2016 | 4409 | 0.05 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.05 | Why? |
| Aminoisobutyric Acids | 1 | 2018 | 31 | 0.05 | Why? |
| Drug Combinations | 2 | 2019 | 3852 | 0.05 | Why? |
| Leukocyte Count | 1 | 2008 | 3178 | 0.05 | Why? |
| Lactams, Macrocyclic | 1 | 2018 | 130 | 0.05 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2021 | 5837 | 0.05 | Why? |
| Inducible T-Cell Co-Stimulator Protein | 1 | 2017 | 6 | 0.04 | Why? |
| Quinoxalines | 1 | 2018 | 95 | 0.04 | Why? |
| Cytokines | 2 | 2019 | 15010 | 0.04 | Why? |
| Leucine | 1 | 2018 | 121 | 0.04 | Why? |
| Benzofurans | 1 | 2018 | 91 | 0.04 | Why? |
| Contraindications, Drug | 1 | 2018 | 281 | 0.04 | Why? |
| Plasma Gases | 1 | 2017 | 25 | 0.04 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2009 | 2262 | 0.04 | Why? |
| Acrylic Resins | 1 | 2017 | 48 | 0.04 | Why? |
| Mice, Inbred NOD | 1 | 2017 | 134 | 0.04 | Why? |
| Mice, Nude | 1 | 2018 | 340 | 0.04 | Why? |
| Cell Self Renewal | 1 | 2017 | 55 | 0.04 | Why? |
| Cell Line, Tumor | 2 | 2018 | 3608 | 0.04 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2021 | 604 | 0.04 | Why? |
| Mice, SCID | 1 | 2017 | 225 | 0.04 | Why? |
| Proline | 1 | 2018 | 345 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.04 | Why? |
| Peptides | 1 | 2009 | 2513 | 0.04 | Why? |
| Extracellular Matrix | 1 | 2017 | 189 | 0.04 | Why? |
| Survivors | 1 | 2008 | 2619 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.04 | Why? |
| Cyclopropanes | 1 | 2018 | 332 | 0.04 | Why? |
| Tissue Scaffolds | 1 | 2017 | 174 | 0.04 | Why? |
| Adsorption | 1 | 2017 | 261 | 0.04 | Why? |
| Alanine Transaminase | 1 | 2002 | 1329 | 0.04 | Why? |
| Tissue Engineering | 1 | 2017 | 190 | 0.04 | Why? |
| Neoplasm Invasiveness | 1 | 2018 | 582 | 0.04 | Why? |
| Antineoplastic Agents | 1 | 2011 | 3550 | 0.04 | Why? |
| TOR Serine-Threonine Kinases | 1 | 2018 | 385 | 0.04 | Why? |
| Symptom Flare Up | 1 | 2019 | 432 | 0.04 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.04 | Why? |
| Virus Activation | 1 | 2019 | 480 | 0.04 | Why? |
| Carbon | 1 | 2017 | 269 | 0.03 | Why? |
| Carcinogenesis | 1 | 2017 | 236 | 0.03 | Why? |
| Chitosan | 1 | 2017 | 196 | 0.03 | Why? |
| Anxiety | 1 | 2020 | 17311 | 0.03 | Why? |
| Patient Selection | 1 | 2008 | 4560 | 0.03 | Why? |
| Databases, Factual | 2 | 2019 | 6248 | 0.03 | Why? |
| Mental Health | 1 | 2020 | 15770 | 0.03 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2017 | 497 | 0.03 | Why? |
| Toll-Like Receptor 7 | 1 | 2017 | 402 | 0.03 | Why? |
| Health Personnel | 2 | 2020 | 29646 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2018 | 11559 | 0.03 | Why? |
| Mycoses | 1 | 2018 | 589 | 0.03 | Why? |
| Interleukins | 1 | 2017 | 762 | 0.03 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1014 | 0.03 | Why? |
| Consensus | 1 | 2006 | 6345 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Evoked Potentials, Somatosensory | 1 | 1990 | 40 | 0.03 | Why? |
| Transfection | 1 | 2014 | 864 | 0.03 | Why? |
| Nomograms | 1 | 2017 | 790 | 0.03 | Why? |
| Evoked Potentials, Visual | 1 | 1990 | 40 | 0.03 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.03 | Why? |
| Cohort Studies | 2 | 2019 | 36005 | 0.03 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 1115 | 0.03 | Why? |
| Pregnancy | 2 | 2018 | 23879 | 0.03 | Why? |
| Sulfonamides | 1 | 2018 | 1294 | 0.02 | Why? |
| Antigens, Viral | 2 | 2009 | 6298 | 0.02 | Why? |
| Clinical Protocols | 1 | 2001 | 2734 | 0.02 | Why? |
| Dimethyl Sulfoxide | 1 | 2009 | 35 | 0.02 | Why? |
| Hepatitis Delta Virus | 1 | 2009 | 54 | 0.02 | Why? |
| Rats | 1 | 2017 | 2764 | 0.02 | Why? |
| Viral Regulatory and Accessory Proteins | 1 | 2014 | 482 | 0.02 | Why? |
| Dendritic Cells | 1 | 2017 | 1330 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2018 | 2115 | 0.02 | Why? |
| HLA-A2 Antigen | 1 | 2009 | 134 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Chronic Disease | 1 | 2002 | 5139 | 0.02 | Why? |
| Multiple Organ Failure | 1 | 2017 | 1724 | 0.02 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.02 | Why? |
| Nanoparticles | 1 | 2018 | 2040 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Gastrointestinal Diseases | 1 | 2020 | 2580 | 0.02 | Why? |
| Hepatitis E virus | 1 | 2009 | 306 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Anticoagulants | 1 | 2006 | 9563 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Gene Expression | 1 | 2014 | 3332 | 0.02 | Why? |
| Models, Molecular | 1 | 2017 | 7616 | 0.02 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.01 | Why? |
| Immunity, Humoral | 1 | 2017 | 4849 | 0.01 | Why? |
| B-Lymphocytes | 1 | 2017 | 4418 | 0.01 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2018 | 5164 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2017 | 11041 | 0.01 | Why? |
| Kidney Transplantation | 1 | 2017 | 5397 | 0.01 | Why? |
| Infant, Newborn | 1 | 2018 | 23105 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2018 | 10083 | 0.01 | Why? |
| Epitopes | 1 | 2009 | 4113 | 0.01 | Why? |
| HIV Infections | 1 | 2001 | 11620 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| United States | 1 | 2020 | 46150 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.01 | Why? |
| Hospitalization | 1 | 2018 | 54280 | 0.01 | Why? |